Medical drugs

CSPC is eligible to receive US$30 million as upfront payment and up to US$1.7 billion in additional payments

China’s ascendence as a drug development powerhouse could threaten US biotechnology

A new wave of cheap weight-loss drugs heralds an existential crisis for the sin economy

Core earnings for the three months ended March rise to US$2.58 per share, while total revenue jumps 8% to US$15.3 billion

Beijing has equally begun to protect its own nascent databases, passing a biosecurity law in 2020

[WASHINGTON, DC] The Trump administration will impose tariffs of as much as 100 per cent on certain imported medicines, albeit with several major exemptions, a maneuver to pressure drugmakers to manuf...

One firm plans to make a semaglutide jab at a starting price of 1,290 rupees a month

The international health governance landscape is at a critical and precarious juncture

This underscores the US drugmaker’s push to diversify beyond its blockbuster drug